TiGenix is a late-stage biomedical company and operates at the cutting edge of regenerative medicine and focuses on the development of innovative local treatments for damaged and osteoarthritic joints. It is the first regenerative medicine company with a clear and single disease-orientated focus.
TiGenix' ambition is to develop a comprehensive solution for treating specific muscolosceletal disorders, a huge and fast growing unmet medical need in our ageing society. TiGenix is exploiting the power of regenerative medicine to develop durable treatments, validated through controlled clinical trials, for these indications.
TiGenix' first product, ChondroCelect, is an improved ACI product, the first to incorporate identity characterization based on in vivo biological function. Designed to guarantee formation of stable hyaline cartilage in vivo, ChondroCelect aims at true functional repair of the damaged joint surface.